- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Farmington Hills Today
By the People, for the People
BTIG Raises Opus Genetics Price Target to $12
Analysts see 188% upside potential for the biotech stock
Mar. 2, 2026 at 4:23pm
Got story updates? Submit your updates here. ›
BTIG Research has raised its price target on shares of Opus Genetics (NASDAQ:IRD) from $7.00 to $12.00, representing a potential upside of 188% from the stock's previous close. The brokerage firm maintained its "buy" rating on the biotech company's stock.
Why it matters
The significant increase in Opus Genetics' price target by a prominent research firm suggests analysts see substantial growth potential for the company's ophthalmic drug development pipeline. This could signal increased investor interest and buying pressure for the stock.
The details
In its research note, BTIG cited Opus Genetics' progress in advancing its clinical programs for refractive and retinal eye disorders. The company's lead product candidates are in various stages of development, targeting unmet needs in the ophthalmic space.
- BTIG Research issued the updated price target and rating on March 2, 2026.
The players
BTIG Research
An investment research and trading firm that provides institutional investors with research, sales, and trading services.
Opus Genetics
A clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of refractive and retinal eye disorders.
What’s next
Investors will be closely watching Opus Genetics' progress in advancing its drug candidates through clinical trials and any further updates from research analysts on the company's growth prospects.
The takeaway
The significant price target increase by BTIG Research underscores the analysts' confidence in Opus Genetics' ability to capitalize on the unmet needs in the ophthalmic drug market, potentially driving substantial returns for investors who believe in the company's long-term growth potential.
